Oxford Nanopore Technologies Plc ONT
LSE · United Kingdom · Electronic Technology
GBp 215.81-1.79 (-0.82%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimesterDr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, joins Aitiologic’s advisory board and participates in the round as an investorDr. Rebecca Ertl, obstetrician-gynecologist and founder of a leading prenatal diagnostics center, appointed Chief Medical Officer VIENNA, S
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
Oxford Nanopore Technologies (LON:ONT) reported first-half revenue growth below its expectations as declines in China, the Middle East and delayed orders in the Americas weighed on performance, while gross-margin expansion and lower operating expenses narrowed its adjusted EBITDA loss. Revenue for
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.